Oncogenic Role of HER3

CME

Deciphering HER3: Biologic Underpinnings, Expression Patterns, and Oncogenic Role

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: December 31, 2024

Expiration: June 30, 2025

Activity

Progress
1 2
Course Completed

References

    1. Boch T, Köhler J, Janning M, et al. Targeting the EGF receptor family in non-small cell lung cancer-increased complexity and future perspectives. Cancer Biol Med. 2022;19:1543-1564.
    2. Diwanji D, Trenker R, Thaker TM, et al. Structures of the HER2–HER3–NRG1β complex reveal a dynamic dimer interface. Nature. 2021;600:339-343.
    3. Dokala A, Thakur SS. Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery. Oncogene. 2016;36:2337-2344.
    4. Lyu H, Han A, Polsdofer E, et al. Understanding the biology of HER3 receptor as a therapeutic target in human cancer. Acta Pharm Sinica B. 2018;8:503-510.
    5. Scharpenseel H, Hanssen A, Loges S, et al. EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients. Sci Rep. 2019;9:7406.
    6. Kumagai T, Tomita Y, Nakatsuka S, et al. HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1. Thorac Cancer. 2018;9:466-471.
    7. Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Therapy. 2008;15:413-448.
    8. Li Q, Zhang R, Yan H, et al. Prognostic significance of HER3 in patients with malignant solid tumors. Oncotarget. 2017;8:67140-67151.
    9. Janne PA, Yu HA, Johnson ML, et al. Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC. J Clin Oncol. 2019;37(15_suppl):9010-9010.
    10. Chao WR, Lee MY, Ruan A, et al. Assessment of HER2 status using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) techniques in mucinous epithelial ovarian cancer: a comprehensive comparison between ToGA biopsy method and ToGA surgical specimen method. PLoS ONE. 2015;10:e0142135.
    11. Ye P, Li F, Wei Y, et al. EGFR, HER2, and HER3 protein expression in paired primary tumor and lymph node metastasis of colorectal cancer. Sci Rep. 2022;12:12894.
    12. Arteaga CL. HER3 and mutant EGFR meet MET. Nat Med. 2007;13:675-677.
    13. Schoenfeld AJ, Chan J, Kubota D, et al. Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer. Clin Cancer Res. 2020;26:2654-2663.
    14. Yonesaka K, Tanizaki J, Maenishi O, et al. HER3 augmentation via blockade of EGFR/AKT signaling enhances anticancer activity of HER3-targeting patritumab deruxtecan in EGFR-mutated non–small cell lung cancer. Clin Cancer Res. 2021;28:390-403.
    15. Uliano J, Corvaja C, Curigliano G, et al. Targeting HER3 for cancer treatment: a new horizon for an old target. ESMO Open. 2023;8:100790-100790.
    16. Gupta B, Wu S, Ou SHI, et al. NRG1 fusions in solid tumors. J Clin Oncol. 2023;41(16 suppl):3132-3132.
    17. Severson E, Achyut BR, Nesline M, et al. RNA sequencing identifies novel NRG1 fusions in solid tumors that lack co-occurring oncogenic drivers. J Mol Diagn. 2023;25:454-466.
    18. ‌Schram A. Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC). Ann Oncol. 2023;34(suppl 2):S755-S851.
    19. Zenocutuzmab PI.
    20. Jänne PA, Baik C, Su WC, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor–resistant, EGFR-mutated non–small cell lung cancer. Cancer Discov. 2021;12:74-89.
    21. Dolgin E. HER3-addicted tumors: how biotechs are closing in. Nat Biotechnol. 2022;40:1157-1159.